Lupin Limited

LUPIN

INE326A01037

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 12:42:40 21/01/2026 pm IST			5-day change	1st Jan Change
2,165.95 ^INR	-0.01%		-1.32%	+2.55%

10:28am	Lupin Signs Licensing and Supply Pact with Galenicum for Injectable Semaglutide	MT
07:57am	Lupin, Galenicum sign license, supply agreement for semaglutide in 23 countries	RE

Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets

Published on 12/05/2025 at 10:10 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Lupin Limited

10:28am	Lupin Signs Licensing and Supply Pact with Galenicum for Injectable Semaglutide	MT
07:57am	Lupin, Galenicum sign license, supply agreement for semaglutide in 23 countries	RE
30/12	Lupin Extends Timeline to Close VISUfarma Acquisition	MT
29/12	Lupin signs exclusive licensing agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist	RE
29/12	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI
24/12	Lilly, Novo lock horns in India's obesity drug race	RE
19/12	Biomarin to acquire Amicus Therapeutics for $4.8 billion	RE
18/12	Lupin signs exclusive licensing agreement with Neopharmed	RE
18/12	Lupin Limited Signs Exclusive Licensing Agreement with Neopharmarm for Gastroenterology Brand Plasil in the Philippines and Brazil	CI
17/12	Lupin receives positive CHMP opinion for biosimilar ranibizumab	RE
17/12	Lupin Limited Receives Positive CHMP Opinion for Biosimilar Ranibizumab	CI
16/12	Lupin gets EIR from US FDA for Nagpur facility	RE
16/12	Lupin Limited Receives EIR from US FDA for its Nagpur Injectable Facility	CI
12/12	India, France seal treaty revamp giving Paris dividend relief, Delhi tax rights	RE
12/12	Indian Stocks Extend Gains on Friday as Global Sentiment Improves After US Rate Cut	MT
12/12	Ozempic launches in India at $24 a week as Novo targets booming diabetes market	RE
12/12	Lupin Ties Up with PolyPeptide Group for Peptide-Based Active Pharmaceutical Ingredients	MT
12/12	Lupin says Lupin Manufacturing Solutions, Polypeptide announce alliance	RE
05/12	Indian Equities Rally on Friday After Central Bank's Rate Cut	MT
05/12	Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	MT
05/12	Lupin receives tentative approval from US FDA for siponimod tablets	RE
05/12	Lupin Limited Receives Tentative Approval from U.S. FDA for Siponimod Tablets	CI
04/12	Lupin enters licensing agreement with Valorum for Armlupeg in U.S.	RE
04/12	Lupin Limited and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States	CI
03/12	Novo Nordisk gears up for December Ozempic launch in India, sources say	RE

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Employees

24,006

Sector

Pharmaceuticals

Calendar

05/02 - Q3 2026 Earnings Release (Projected)

More about the company